Cellebrite DI Ltd. (NASDAQ:CLBT) Stock Position Increased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lifted its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 37.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,811 shares of the company’s stock after buying an additional 7,301 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Cellebrite DI were worth $591,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of CLBT. FMR LLC raised its stake in shares of Cellebrite DI by 136.3% in the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company’s stock worth $94,586,000 after buying an additional 3,239,307 shares in the last quarter. Principal Financial Group Inc. bought a new stake in shares of Cellebrite DI in the 3rd quarter worth $23,402,000. Lord Abbett & CO. LLC bought a new stake in shares of Cellebrite DI in the 3rd quarter worth $11,523,000. Summit Partners Public Asset Management LLC bought a new stake in shares of Cellebrite DI in the 3rd quarter worth $9,274,000. Finally, Telemark Asset Management LLC bought a new stake in shares of Cellebrite DI in the 3rd quarter worth $6,736,000. Institutional investors own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 target price on shares of Cellebrite DI in a research report on Friday, February 14th. Craig Hallum boosted their target price on Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Finally, Lake Street Capital boosted their target price on Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI has an average rating of “Buy” and an average target price of $23.43.

Cellebrite DI Trading Up 0.3 %

NASDAQ:CLBT opened at $18.56 on Friday. The firm has a market capitalization of $3.82 billion, a price-to-earnings ratio of -13.35, a PEG ratio of 4.27 and a beta of 1.47. Cellebrite DI Ltd. has a 1-year low of $10.24 and a 1-year high of $26.30. The business’s fifty day moving average price is $22.31 and its 200 day moving average price is $19.61.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Equities analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.